Share
- Release Date: 12/09/12 18:15
- Summary: GENERAL: BLT: New Study confirms effectiveness of BLIS K12
- Price Sensitive: No
- Download Document 3.13KB
BLT
12/09/2012 16:15
GENERAL
REL: 1615 HRS BLIS Technologies Limited
GENERAL: BLT: New Study confirms effectiveness of BLIS K12
New Study confirms effectiveness of BLIS K12
BLIS Technologies Ltd (NZX:BLT) announces the recent independent publication
by a Swiss research team at the University of Basel, evaluating the oral
cavity probiotic, BLIS K12(TM) for its ability to inhibit bacteria
responsible for the severe bad breath in the oral cavity (also known as
halitosis). The study entitled "Antimicrobial activity of Streptococcus
salivarius K12 on bacteria involved in oral malodour" has been published in
the international science journal, Archives of Oral Biology (2012).
This study confirms an earlier clinical study of 23 subjects by Dr J Burton
and co-workers, (published in the Journal of Applied Microbiology) where S.
salivarius K12 was shown to be effective at significantly reducing the levels
of sulphur-compound producing bacteria in the mouth, which are responsible
for chronic bad breath and halitosis.
It is estimated that around 49 million people in the United States alone,
worry "a lot" about bad breath and nearly 10 million live with bad breath,
which impacts their lives a moderate or severe amount. US consumers spent
over $US 1 billion on mouth fresheners, mouth washes and dental rinses in
2011 according to the market research company, Euromonitor.
BLIS K12 is a specific strain of S. salivarius; a species of beneficial
bacteria which is found naturally occurring in the mouth of healthy
individuals. In addition to being part of the dominant healthy species of the
mouth, this probiotic strain also secretes powerful antimicrobial molecules
called BLIS: Bacteriocin-Like-Inhibitory Substances to help provide a natural
long term protection from bad breath as well as support our oral immune
system's natural defenses.
The objective of the study at the University of Basel, Switzerland was to
investigate the antimicrobial activity of BLIS K12 against several bacteria
involved in chronic and severe halitosis including such clinically relevant
strains as Solobacterium moorei, Atopobium parvulum and Eubacterium sulci.
The study results found that BLIS K12 could inhibit all tested bacteria
responsible for oral malodour. The authors concluded that this study further
supports the potential of BLIS K12 as a valuable candidate for inclusion in
therapies for halitosis sufferers and offers potential long-term support for
sufferers of this disease, through the direct inhibition of the responsible
malodor-causing bacteria.
"This research paper represents further evidence that the BLIS K12 probiotic
plays an important role in maintaining good oral health by protecting the
mouth against invading pathogens" said Dr Barry Richardson, Chief Executive
of BLIS Technologies. "We believe that the data in this model strongly points
to a beneficial effect in the human oral cavity and we expect further human
studies to confirm this effect."
# # #
YOUR CONTACT:
Grant Washington-Smith
BLIS Technologies Ltd
PO Box 56 ?87 St David Street ?Dunedin?New Zealand
Phone +64 (3) 479 5337
www.blis.co.nz
End CA:00227215 For:BLT Type:GENERAL Time:2012-09-12 16:15:19
